Bispecific Antibodies

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY 03/13/2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

$Epcoritamab Plus R2 Redefines the Standard of Care in Relapsed or Refractory Follicular Lymphoma: Insights from the EPCORE FL-1 Trial$

Hematology-Oncology news

Epcoritamab Plus R2 Redefines the Standard of Care in Relapsed or Refractory Follicular Lymphoma: Insights from the EPCORE FL-1 Trial

By MedXY 01/14/2026

The Phase 3 EPCORE FL-1 trial demonstrates that adding epcoritamab to lenalidomide and rituximab (R2) significantly improves progression-free survival (HR 0.21) and response rates in relapsed/refractory follicular lymphoma, establishing a potent new chemotherapy-free treatment paradigm.

$Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention$

Hematology-Oncology news Oncology

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

By MedXY 12/18/2025

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high rates of complete response and minimal residual disease negativity.